Medtronic

Fully Implantable Left Ventricular Assist Device (LVAD) for patients with advanced heart failure,

image343

 

Medtronic Receives FDA “Breakthrough Device Designation” for Developing Fully Implantable Heart Pump

Tue October 29, 2019 12:00 PM|GlobeNewswire|About: MDT

DUBLIN, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)


 https://www.medtronic.com/us-en/index.html 

Resolute Onyx™ DES

image344

 

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

Thu September 26, 2019 1:50 PM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT

MiniMed™ 670G Insulin Pump System

image345

 

Medtronic Announces Reimbursement in Germany for MiniMed™ 670G Insulin Pump System for Individuals with Type 1 Diabetes

Mon September 9, 2019 9:00 AM|GlobeNewswire|About: MDT

DUBLIN, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

Patient Programmer technology for Deep Brain Stimulation (DBS) therapy

image346

 

Medtronic Launches New Activa™ Patient Programmer for DBS Therapy

Wed October 30, 2019 2:00 PM|GlobeNewswire|About: MDT

System Offers at Home Therapy Management for DBS patients
Using Patient-Friendly Consumer Technology

DUBLIN and SAN JOSE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)


 www.medtronic.com 

Bluetooth® enabled MiniMed(TM) 780G advanced hybrid closed loop (AHCL)

image347

Medtronic Initiates Pivotal Trial for Bluetooth Enabled MiniMed(TM) 780G Advanced Hybrid Closed Loop System Designed to Automate Correction Bolusing

Sat June 8, 2019 1:00 PM|InPublic US|About: MDT

DUBLIN - June 8, 2019 - Medtronic plc (MDT)

abbott

Alinity™ s System

image348

 

The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening

Mon October 21, 2019 9:00 AM|PR Newswire|About: ABT 


 PR Newswire

ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (ABT


 https://www.prnewswire.com/news-releases/the-australian-red-cross-blood-service-selects-abbotts-alinity-s-solution-for-blood-and-plasma-screening-300941474.html 


 https://seekingbiotechalpha.com/medtech 

image349

 Abbott's Tendyne mitral valve shows positive effect in global study

image350

 NEW COVERAGE DECISION EXTENDS ABBOTT'S INNOVATIVE PAIN THERAPY OPTION TO 22 MILLION AMERICANS LIVING WITH CHRONIC PAIN 

image351

 ABBOTT'S FREESTYLE® LIBRE 14 DAY FLASH GLUCOSE MONITORING SYSTEM NOW APPROVED IN U.S. 

image352

 ABBOTT EXPANDS ITS DIRECTIONAL DEEP BRAIN STIMULATION THERAPY BY OFFERING NEW MR-CONDITIONAL LABELING 

image353

 ABBOTT INTRODUCES BREAKTHROUGH POINT-OF-CARE TEST, THE M-PIMA™ HIV-1/2 VIRAL LOAD (VL), AT AIDS 2018 AMSTERDAM 

Abiomed

Impella 5.5™ with SmartAssist® Heart Recovery, Rest, Preservation

image354

 

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Thu October 31, 2019 7:02 AM|Business Wire|About: ABMD

DANVERS, Mass.--(BUSINESS WIRE)


 https://www.businesswire.com/news/home/20191031005267/en/ 


 https://www.impella.com/ 


 http://www.abiomed.com/ 

Impella 5.0 and Impella LD

image357

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Mon May 13, 2019 12:00 PM|Business Wire|About: ABMD

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed  (ABM

Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

image359

  

Abiomed Receives FDA PMA Approval for Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Wed September 25, 2019 7:05 AM|Business Wire|About: ABMD

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed’s (NASDAQ: ABMD)

illumina

image360

 Illumina Receives Approval of MiSeq™Dx System in China

image361

 Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology

image362

 Illumina Launches iSeq 100 Sequencing System

image363

 Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies

VeriSeq™ NIPT Solution v2

image364

June 04, 2019 09:00 AM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN

Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions

Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing 


image365

 Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Intuitive surgical

image366

 Intuitive Surgical Announces Innovative Single Port Platform — the da Vinci SP® Surgical System 

image367

 Intuitive Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies 

image368

 Intuitive Surgical Receives FDA Clearance for First 60mm Stapler 

image369

 New Study Shows Robotic-Assisted Surgery Benefits for Inguinal Hernia Repair 

image370

 New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform 

image371

 Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System 

Varian

Varian ProBeam 360 System Selected by The Ohio State University

image373

 

Varian ProBeam 360 System Selected by The Ohio State University for New Proton Therapy Center

Thu October 24, 2019 8:15 AM|PR Newswire|About: VAR 


 https://www.prnewswire.com/news-releases/varian-probeam-360-system-selected-by-the-ohio-state-university-for-new-proton-therapy-center-300944519.html 


 https://www.varian.com/ 


 https://cancer.osu.edu/ 

Varian ProBeam 360 Proton Therapy System Selected by Penn Medicine

image374

 

Varian ProBeam 360 Proton Therapy System Selected by Penn Medicine for Use in Second Treatment Center

Wed October 23, 2019 4:20 PM|PR Newswire|About: VARPR Newswire

PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR)


 https://www.prnewswire.com/news-releases/varian-probeam-360-proton-therapy-system-selected-by-penn-medicine-for-use-in-second-treatment-center-300943915.html 


 https://www.varian.com/ 

Karolinska University Hospital Solna - HDR Brachytherapy Cancer Treatments = VAR Bravos Afterloader

image375

 

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR 


 https://www.prnewswire.com/news-releases/karolinska-university-hospital-solna-delivers-hdr-brachytherapy-cancer-treatments-with-varian-bravos-afterloader-system-300889555.html 

Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology

image376

 

Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology

Fri September 13, 2019 8:15 AM|PR Newswire|About: VAR

PALO ALTO, Calif. and PHILADELPHIA, Sept. 13, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR) 


 https://www.prnewswire.com/news-releases/varian-and-oncora-partner-to-accelerate-precision-medicine-in-radiation-oncology-300917662.html 


 https://www.varian.com/ 

Varian Reports Results for Fourth Quarter and Full Fiscal Year 2019

image377

 

Varian Reports Results for Fourth Quarter and Full Fiscal Year 2019; Appoints New President of Interventional Oncology Solutions and New Chief Financial Officer

Wed October 23, 2019 4:01 PM|PR Newswire|About: VAR

PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ --

Fourth Quarter 2019 Summary


 https://www.prnewswire.com/news-releases/varian-reports-results-for-fourth-quarter-and-full-fiscal-year-2019-appoints-new-president-of-interventional-oncology-solutions-and-new-chief-financial-officer-300944300.html